Strategy Driven

JULY 13, 2011

While you can find numerous books focused on the topic of corporate finance, few offer the type of information managers need to help them make important decisions day in and day out. Examines ways to maintain and grow value through mergers, acquisitions, and portfolio management.

ROIC 62

ROIC Balanced Scorecard Metrics McKinsey 62

Marshall Goldsmith

FEBRUARY 8, 2018

Thinkers50 – World’s Most Influential Management Thinkers. Called ‘The Academy Awards of Leadership’ by the Economist, Thinkers50 is the world’s most reliable resource for identifying, ranking and sharing the leading management ideas of our age. World authority on project management. Co-author: Predictable Magic.

Executive Coaching 70

Executive Coaching CEO Magazine Banking 70

Harvard Business Review

DECEMBER 20, 2011

The Lipitor story seems to be about a managed end: the highly anticipated demise (due to the expiration of its patent last Nov. Apple use life-cycle management to explore a new way to drive the business and business model forward. Diplomat will sell mail-order branded Lipitor at generic prices. Both Pfizer and.

Disintermediation 14

Disintermediation Industry Pharmaceuticals Price 14

Harvard Business Review

MAY 26, 2016

That is good news for managers and investors. While a dynamic, competitive economy rewards innovative firms with high profits and punishes poor performers with low profits, sustained aggregate profits suggest, instead, that firms are able to get away with higher prices because competition is limited. Profits are up.

Pharmaceuticals 9

Pharmaceuticals Politics Price Chemicals 9

Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. But why not? Lower costs, more true innovation.

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

APRIL 2, 2018

There is an abundance of high-quality comparative effectiveness data for pharmaceuticals, largely because of the drug approval process, but there’s less data on the value of other expensive investments into health, such as doctor visits and hospitalizations. (For

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

MAY 31, 2018

The pharmaceutical company Valeant raised the price of Cuprimine — invented in 1956 and used to treat Wilson’s disease, a rare condition in which the body cannot process copper — from about $500 to about $24,000 for a 30-day supply, causing outrage from consumers. And the stakes are too high not to try.

CEO 8

CEO Short-term Long-term McKinsey 8

Harvard Business Review

JANUARY 13, 2015

In pharmaceuticals, there are blockbuster drugs targeted at mass-markets segments. But insurers pay this price because Soliris is the only safe and effective treatment for these diseases and that price is less than the total cost of alternative treatments. But there is also Nordstrom, Louis Vuitton, and many high-end boutiques.

Market Segmentation 8

Market Segmentation Mass Marketing Price Pharmaceuticals 8

Harvard Business Review

JULY 8, 2016

They’ve simply undercut Western competitors by offering cheaper prices. Far from being disruptive, Chinese textile, apparel, appliances, metal, and solar and wind players have done little that has been different from the practices they found in these industries when they entered them. They have been displacers, not disrupters.

Business Model 9

Business Model Innovation Company Apparel 9

Harvard Business Review

NOVEMBER 8, 2018

Consider the following scenario: A manager wants to purchase some computer software for her business. The manager peruses that company’s website and requests more information by entering data about her needs through a webform. The mounting number of inconsistencies and redundancies confuse and frustrate the manager.

Marketing 9

Marketing Team Software Pharmaceuticals 9

Harvard Business Review

DECEMBER 14, 2017

To be the change that many desire, these new mergers and acquisitions, and the others that will likely follow, must produce a higher-quality product for consumers (and satisfy physicians and other health professionals) at an affordable price. The answer is far from certain, and the uncertainties differ for the two mergers.

Health Care 8

Health Care System Insurance Pharmaceuticals 8

Harvard Business Review

DECEMBER 22, 2016

Indeed, in the 1980s Peter Drucker, the management expert who correctly understood that the purpose of the business corporation is to create customers rather than profits for shareholders, touted 20:1 as a sufficiently high ratio for any company in any country, including the United States.

CEO 8

CEO Black-Scholes Price Merton 8

The Practical Leader

APRIL 6, 2022

McGill University management professor and author, Henry Mintzberg said, “an organization without human commitment is like a person without a soul: Skeleton, flesh, and blood may be able to consume and to excrete, but there is no life force.” ” Pharmaceutical company: “ Preserving and improving human life.”

Mintzberg 111

Mintzberg Pharmaceuticals Energy McKinsey 111

Harvard Business Review

MAY 7, 2015

That may be difficult to quantify (more on that below) but it’s important for companies to try to understand because it affects how much you’re willing to pay for their product (typically, the higher the EVC, the higher the price they can charge you) and how likely you are to continue to use it. It’s appropriately priced.

Price 8

Price Venture Capitalist Incentives Cost 8

Harvard Business Review

JUNE 14, 2017

Information that would once have been proprietary — and premium-priced — is now widely available, for free. Some firms have managed it, in healthcare and in other arenas — think of QuintilesIMS as a source of pharmaceutical sales data, Nielsen as the authority on TV viewer habits, and the U.S. demographics.

Health Care 8

Health Care Levitt Competitive Advantage Pharmaceuticals 8

Harvard Business Review

JUNE 16, 2016

Pharmaceutical companies spend millions upon millions preparing meticulous plans for new drug launches – and yet their route-to-market strategies haven’t changed in decades, even though the reality of the market has. We must start to think differently about how business, management, and strategic intelligence works.

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

MAY 24, 2012

Every large financial services company has instituted risk management, but that hasn't prevented risky behavior in the form of office politics and personality conflict — as the JP Morgan trading debacle has demonstrated. Risk management isn't exclusive to banking. Risk management isn't exclusive to banking.

Merchandising 10

Merchandising Risk Management Supply Chain Retail 10

Harvard Business Review

MARCH 2, 2011

Marakon , which put value-based management at the core of its strategy concentration, is essentially defunct. Undertakings with $20 million price tags such as the post-merger integration of a giant pharmaceutical client and its equally humongous acquisition. Monitor & Co., He is based in New York City and Boston.

Consultative 15

Consultative Strategy McKinsey Porter 15

Strategy Driven

MARCH 18, 2011

Walmart wrings maximum efficiency from its supply chain by integrating four capabilities – aggressive vendor management, expert point-of-sale data analytics, superior logistics, and rigorous working-capital management – that together deliver ‘everyday low prices’ to consumers.

Resources 52

Resources Industry System Strategy 52

Harvard Business Review

APRIL 4, 2018

Or the notorious case of Martin Shkreli, the former CEO of Turing Pharmaceuticals, who failed to apologize for dramatically raising the price of a life-saving drug. These figures were skewered for being egotistical, arrogant, and refusing to admit their mistakes. Encourage creativity by helping team members exchange information.

Creativity 11

Creativity Pharmaceuticals Learning-by-Doing Team 11

Harvard Business Review

DECEMBER 18, 2014

Since that first foray into negotiating lower prices for commodity items, these coalitions have expanded their reach to include aggregation of supply purchases of items such as implantable medical devices, as well as drugs, capital purchases like CAT scan equipment and even electricity.

Health Care 8

Health Care Retail Mayo Pharmaceuticals 8

Harvard Business Review

NOVEMBER 24, 2015

But those numbers are the equivalent of the price of the car, not the added value that the new ownership will produce after the merger. Joint value in combinations typically comes from one of four sources: increased scale, expanded scope, improvements in management coordination, and expansion of future options.

Pharmaceuticals 8

Pharmaceuticals Cost Airlines Productivity 8

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. There are management tools and incentives in place to encourage a focus on results and the end goals. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

JUNE 16, 2011

Ask a buy-side analyst why Amazon or Apple fetches the price-earnings multiple they do, and inevitably the conversation turns to things like their ability to innovate, their capacity to capture and grow the best talent, their skill at managing brand and vendor relationships or ecosystems. If you can't measure it, how can you manage it?

Intangible Assets 15

Intangible Assets Analysis Pharmaceuticals Innovation 15

Harvard Business Review

SEPTEMBER 13, 2011

After all, positive results attract investors, raise stock prices, reinforce customers, draw talent, and more. Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago.

Short-term 14

Short-term Pharmaceuticals Long-term Maturity 14

Harvard Business Review

OCTOBER 28, 2011

As such, their performance, along with the CEO's, is evaluated by the performance of the stock price. If the stock price underperforms the median of a comparator group over those time frames, a shareholder advisory firm may recommend that shareholders vote against their election.

CEO 10

CEO Short-term Long-term Restructuring 10

Harvard Business Review

FEBRUARY 24, 2015

Conversely, the business may be an “unpolished diamond” that was neglected by its former management for too long and whose value is just waiting to be unlocked. Does the business have a complete, balanced, and cohesive management team? Are the management team and owners prepared to abandon business as usual?

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

NOVEMBER 8, 2017

The rising flood of hardware, pharmaceuticals, and technical expertise from American manufacturers and hospital companies, which is connected to the needs of a growing number of hospitals, is also pushing many systems closer to the U.S. Over the same period, pharmaceutical exports have doubled. Insight Center. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

MAY 5, 2016

However, oil prices have dropped more than 60% since the interim nuclear deal in November 2013. more competition to reduce consumer prices, sharing international best practices, technology transfer, public-private partnerships) needed to boost the economy’s health. This dynamic can stall important change (e.g., The Opportunities.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

MARCH 27, 2018

“It’s no good fighting an election campaign on the facts,” Cambridge Analytica’s managing director told an undercover reporter, “because actually it’s all about emotion.” Ordinarily the harm from monopolies are higher prices, less output, or reduced quality. James Graham/Getty Images.

Company 9

Company Advertising Incentives Engineering 9

Harvard Business Review

JANUARY 31, 2013

Pharmaceutical companies are mastering bio-engineering techniques that will help develop personalized medicines. Commodity prices have risen, wiping out the declines that marked most of the 20th century and wages are rising rapidly in what have been regarded as low-wage locations such as coastal China. but also the risks.

Globalization 8

Globalization Supply Chain Pharmaceuticals McKinsey 8

Harvard Business Review

SEPTEMBER 14, 2017

A less aggressive mix (say 75:25) is typical in industries such as pharmaceuticals that want salespeople to focus on customer education, and for technical sales jobs that have a large problem-solving component. A very aggressive mix (say 0:100) is common in industries such as insurance that use independent contractors as sales agents.

Motivation 8

Motivation Incentives Franchising Short-term 8

Harvard Business Review

APRIL 28, 2011

For example, a major pharmaceutical company discovered that consumers' incredibly loyalty to one of its OTC products had very little to do with its product efficacy or branding. After senior managers recovered from shock, they quickly concluded that "hostage taker" was not the consumer strategy they wanted.

Loyalty 15

Loyalty Brand CEO Pharmaceuticals 15

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 7, 2015

They allow managers to suspend normal rules in an acceptable way and they provide an effective audiovisual medium for absorbing ideas. People Express, for example, is a business simulator that provides players with a rich inside perspective on starting and managing an airline.

Seminar 8

Seminar Learning Curve Strategy Comparison 8

Harvard Business Review

JANUARY 5, 2018

For example, in 2009 professors Brian Becker, Mark Huselid, and Richard Beatty estimated that in most companies less than 15% of jobs are what they call strategic positions and said management should focus “disproportionate investments” on finding A players for those jobs. Connectors in the middle. High-potential future leaders.

McKinsey 8

McKinsey Human Resources Reputation Brand 8

Harvard Business Review

FEBRUARY 11, 2016

McKesson, the US-based pharmaceutical and health-care giant, benefits from external expertise as a strategic extension of its resources in areas such as business strategy and logistics support. ” Most managers would never dream of treating externals like internals. One of the main problems is decision making. Adapted from.

Agility 8

Agility Organization Resources Fixed Costs 8